Abstract: Disclosed are methods and compositions for diagnosis, imaging, and treating one or more mammalian diseases, including, for example, treatment, prophylaxis, and/or amelioration of one or more symptoms of a human cancer. Disclosed are compositions and methods for the treatment and amelioration of one or more symptoms of a disease, and in exemplary embodiments, for use as an immunotherapeutic.

Abstract: Disclosed are compositions and methods relating to nucleic acid aptamers that specifically target CD38 protein and also selective binding to CD38-expressing cells. The ligand-drug conjugates specifically target CD38-expressing cancer cells and subsequently internalize into the cell.

Abstract: Disclosed are methods and compositions for diagnosis, imaging, and treating one or more mammalian diseases, including, for example, treatment, prophylaxis, and/or amelioration of one or more symptoms of a human cancer. In particular, compositions and methods are provided for the treatment and amelioration of one or more symptoms of lymphoma, and in exemplary embodiments, for treatment of anaplastic large cell lymphoma in humans.

Abstract: Disclosed are compositions and methods relating to nucleic acid aptamers that specifically target CD117 protein and also selective binding to CD117-expressing cells. The ligand-drug conjugates specifically target CD117-expressing cells and subsequently internalize into the cells, leading apoptosis, growth inhibition, and death of cells of interest and no off-target toxicity to CD117-negative normal cells.

Abstract: Disclosed are methods and compositions for the detection of one or more different types of cellular biomarkers in a biological sample, and in particular, methods and compositions for the rapid, one-step, highly-cell specific detection of circulating tumor cells from minute quantities of mammalian biological fluids, including, for example, from a single drop of human blood. In certain embodiments, distinctly-labeled, multi-aptamer detection reagents are provided for detecting and quantitating selected cancer cells in clinical samples such as patient specimens and/or tissues. Aptamer-based imaging methodologies are also provided for use in a variety of diagnostic assay protocols.

Abstract: Disclosed are compositions and methods relating to nucleic acid aptamers that specifically target CD38 protein and also selective binding to CD38-expressing cells. The ligand-drug conjugates specifically target CD38-expressing cancer cells and subsequently internalize into the cell.

Abstract: Disclosed are compositions and methods relating to nucleic acid aptamers that specifically target CD117 protein and also selective binding to CD117-expressing cells. The ligand-drug conjugates specifically target CD117-expressing cells and subsequently internalize into the cells, leading apoptosis, growth inhibition, and death of cells of interest and no off-target toxicity to CCD117-negative normal cells.

Abstract: Disclosed are methods and compositions for the detection of one or more different types of cellular biomarkers in a biological sample, and in particular, methods and compositions for the rapid, one-step, highly-cell specific detection of circulating tumor cells from minute quantities of mammalian biological fluids, including, for example, from a single drop of human blood. In certain embodiments, distinctly-labeled, multi-aptamer detection reagents are provided for detecting and quantitating selected cancer cells in clinical samples such as patient specimens and/or tissues. Aptamer-based imaging methodologies are also provided for use in a variety of diagnostic assay protocols.